Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study

References

• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-small cell lung cancer, Version 4.2016. NCCN, 2016. Fort Washington, PA https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Jun 10, 2016
   Google Scholar
• Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice guideline update. J Clin Oncol 2015;33:3488–515
   PubMed Web of Science ®Google Scholar
• Pereira JR, Cheng R, Orlando M, et al. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer. Drugs R D 2013;13:289–96
   PubMedGoogle Scholar
• Zukin M, Barrios CH, Pereira JR, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013;31:2849–53
   PubMed Web of Science ®Google Scholar
• Schuette WH, Gröschel A, Sebastian M, et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 2013;14:215–23
   PubMed Web of Science ®Google Scholar
• Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii27–39
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432–40
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895–902
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–51
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11(2 Pt 1):690–6
   PubMed Web of Science ®Google Scholar
• Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005;104:2449–56
   PubMed Web of Science ®Google Scholar
• Okamoto I, Aoe K, Kato T, et al. Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naive patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs 2013;31:1275–82
   PubMed Web of Science ®Google Scholar
• Rodrigues-Pereira J, Kim JH, Magallanes M, et al. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:1907–14
   PubMed Web of Science ®Google Scholar
• Socinski MA, Raju RN, Stinchcombe T, et al. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5:1963–9
   PubMed Web of Science ®Google Scholar
• Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2015;10:134–42
   PubMed Web of Science ®Google Scholar
• Okamoto I, Schuette WHW, Stinchcombe TE, et al. Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies. Curr Med Res Opin 2017
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–205
   PubMed Web of Science ®Google Scholar
• Greenland S, Robins JM, Pearl J. Confounding and collapsibility in causal inference. Statist Sci 1999;14:29–46
   Web of Science ®Google Scholar
• Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003;14:680–6
   PubMed Web of Science ®Google Scholar
• Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci 2010;25:1–21
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9
   PubMed Web of Science ®Google Scholar
• Simon MS, Lamerato L, Krajenta R, et al. Racial differences in the use of adjuvant chemotherapy for breast cancer in a large urban integrated health system. Int J Breast Cancer 2012: published online 20 May 2012, doi:10.1155/2012/453985
   PubMedGoogle Scholar
• Paz-Ares LG, Zimmermann A, Ciuleanu TE, et al. Abstract 188: Meta-analysis examining impact of age on pemetrexed (pem) efficacy for the treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2014;90(5S):A188
   Google Scholar
• Pallis AG, Gridelli C, Wedding U, et al. Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol 2014;25:1270–83
   PubMed Web of Science ®Google Scholar
• Gridelli C, de Marinis F, Thomas M, et al. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. J Thorac Oncol 2014;9:991–7
   PubMed Web of Science ®Google Scholar
• Sakata S, Sasaki J, Saeki S, et al. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002. Oncology 2015;88:201–7
   PubMed Web of Science ®Google Scholar